An open label pilot study of the effects of memantine administration on FDG-PET [fluoro 2 deoxy D glucose positron emission tomography] in frontotemporal dementia.

Trial Profile

An open label pilot study of the effects of memantine administration on FDG-PET [fluoro 2 deoxy D glucose positron emission tomography] in frontotemporal dementia.

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Jun 2015

At a glance

  • Drugs Memantine (Primary)
  • Indications Dementia
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Jun 2012 Actual patient number is 17 according to ClinicalTrials.gov.
    • 01 Jun 2012 Actual end date (Jun 2012) added as reported by ClinicalTrials.gov.
    • 01 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top